Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Description

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Conditions

Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Condition
Advanced Cancer
Intervention / Treatment

-

Contacts and Locations

Birmingham

ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294

Anchorage

Alaska Oncology and Hematology, Anchorage, Alaska, United States, 99508

Phoenix

Mayo Clinic Arizona - Phoenix Campus, Phoenix, Arizona, United States, 85054

Scottsdale

Local Institution - 001-807, Scottsdale, Arizona, United States, 85258

Tucson

Local Institution - 001-873-A, Tucson, Arizona, United States, 85704

Tucson

USOR - Arizona Oncology - Tucson - Rudasill, Tucson, Arizona, United States, 85704

Bellflower

Local Institution - 001-840-B, Bellflower, California, United States, 90706

Beverly Hills

Beverly Hills Cancer Center, Beverly Hills, California, United States, 90211

Duarte

City of Hope - Duarte (Main Campus), Duarte, California, United States, 91010

Dublin

Local Institution - 001-850-K, Dublin, California, United States, 94568

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
  • * Unresectable or metastatic disease
  • * Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
  • * Adequate organ function
  • * History of intestinal disease or major gastric surgery or inability to swallow oral medications
  • * Other active cancer

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mirati Therapeutics Inc.,

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

2026-01-16